Such discrepancies in the robustness of PD-L1 status to predict the efficacy to anti-PD-L(1) therapy in the early vs metastatic cancer setting have been also reported in triple-negative breast cancer51,52. Here, CD274 is linked to metastatic malignant neoplasm.